Open AccessEffect of Proton Pump Inhibitors on the Serum Concentrations of the Selective Serotonin Reuptake Inhibitors Citalopram, Escitalopram, and Sertraline
Author(s) -
Caroline Gjestad,
Andreas Austgulen Westin,
Eirik Skogvoll,
Olav Spigset
Publication year - 2015
Publication title -
therapeutic drug monitoring
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.649
H-Index - 93
eISSN - 1536-3694
pISSN - 0163-4356
DOI - 10.1097/ftd.0000000000000101
Subject(s) - esomeprazole , citalopram , escitalopram , sertraline , omeprazole , lansoprazole , pharmacology , pantoprazole , chemistry , proton pump inhibitor , serotonin reuptake inhibitor , medicine , antidepressant , hippocampus
The selective serotonin reuptake inhibitors (SSRIs) citalopram, escitalopram, and sertraline are all metabolized by the cytochrome P-450 isoenzyme CYP2C19, which is inhibited by the proton pump inhibitors (PPIs) omeprazole, esomeprazole, lansoprazole, and pantoprazole. The aim of the present study was to evaluate the effect of these PPIs on the serum concentrations of citalopram, escitalopram, and sertraline.